Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $75.56 Consensus Price Target from Brokerages
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given an average rating of “Moderate Buy” by the sixteen analysts that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong […]
More Stories
Spectris (OTCMKTS:SEPJY) versus Acerinox (OTCMKTS:ANIOY) Head to Head Comparison
Acerinox (OTCMKTS:ANIOY – Get Free Report) and Spectris (OTCMKTS:SEPJY – Get Free Report) are both basic materials companies, but which...
XOS (NASDAQ:XOS) and Metso Oyj (OTCMKTS:OUKPF) Head-To-Head Comparison
XOS (NASDAQ:XOS – Get Free Report) and Metso Oyj (OTCMKTS:OUKPF – Get Free Report) are both industrials companies, but which...
Q4 2024 EPS Estimates for Citigroup Inc. (NYSE:C) Reduced by Seaport Res Ptn
Citigroup Inc. (NYSE:C – Free Report) – Analysts at Seaport Res Ptn cut their Q4 2024 earnings per share (EPS)...
Brokers Issue Forecasts for BrainsWay Ltd.’s FY2024 Earnings (NASDAQ:BWAY)
BrainsWay Ltd. (NASDAQ:BWAY – Free Report) – Stock analysts at Northland Capmk lifted their FY2024 earnings per share estimates for...
Q1 2025 EPS Estimates for Morgan Stanley Raised by Seaport Res Ptn (NYSE:MS)
Morgan Stanley (NYSE:MS – Free Report) – Equities research analysts at Seaport Res Ptn upped their Q1 2025 EPS estimates...
Q4 2024 EPS Estimates for STERIS’ (TSE:STE) Cut by Analyst
STERIS’ (TSE:STE – Free Report) – Equities research analysts at Atb Cap Markets cut their Q4 2024 earnings per share...